Nested Applications

VIE23 Database


EFORT invites you to browse through the Exhibitors Database of the 24th EFORT Annual Congress Vienna 2023 which represents those exhibitors that have already committed to and confirmed their presence at the EFORT Congress to be held in Vienna, Austria from 24 to 26 May 2023. 

Should you wish to exhibit, please check the online EFORT WEBSHOP.

EFORT Industry Database

BioVico Medical Biotech

Hutnicza 15B
81-061 Gdynia
Phone: +48 58 660 44 88
About Us

Advanced medical biotechnology

We specialize in medical biotechnology. Our business is based on the implementation of our own innovative products, providing comprehensive solutions tailored to the needs of patients around the world.

We are Polish company that designs innovative medical solutions. Movement and dynamic are our specialty. We aim for patients'​ motor activation using advanced products, dietary supplements, and materials used in endoprosthetics and traumatology.

We carry out complex research projects – from designing the composition and formula, through specialist tests and analysis, to final production of medical preparations. In this way, we reliably connect the care of the highest quality and presumed effectiveness of solutions signed with Biovico brand.

Area of Business: Pharmaceutical Orthopaedic Industry
Category: Medical devices and Biotechnology
Number of Employees worldwide: 51-200 employees
Founded in: 2008
Biolevox™ HA hyaluronic acid, an intraarticular gel 2.2%, a pre-filled syringe 2 ml
Biolevox™ HA is a 2.2% hyaluronic acid gel for an intraarticular injections in a 2 ml pre-filled syringe. Biolevox™ HA helps to reduce pain in order to facilitate daily activities. It protects articular cartilage from further degeneration. As one of the few, it contains such high concentration of hyaluronic acid. Treatment with three doses may provide more than twice the amount of acid than the other formulations of the same type. Biolevox™ HA 2.2% maintains the highest quality standards for medical products.
Biolevox™ HA mini Hyaluronic acid, 1 ml of intra – articular gel 1,6% in a pre-filled syringe
Biolevox™ HA MINI contains hyaluronic acid with optimally high physicochemical parameters, such as molecular weight and concentration. This guarantees the desired mechanical function after injection to the joint and provides expected clinical result. Biolevox™ HA MINI is intended mostly for small joints, for instance: temporomandibular joint, facet joint, metatarsophalangeal joint, carpometacarpal joint, interphalangeal joints. Intra-articular injection of Biolevox™ HA MINI supplements synovial fluid and participates in the nutrition of the cartilage. Already after the first injection, joint mobility should be improved and pain associated with degenerative changes relieved.
Biolevox™ HA One
hyaluronic acid, an intraarticular gel 2.5%, a pre-filled syringe 4.8 ml. Biolevox™ HA ONE 2.5% is a hyaluronic acid gel for an intraarticular injections in a 4.8 ml pre-filled syringe. Sodium hyaluronate obtained by bacterial fermentation is used as a viscoelastic gel in osteoarthritic joint. Hyaluronic acid role in joint is to facilitate the joint movement, relief pain, protect intra-articular cartilage and stimulate the production of endogenous hyaluronic acid. As a one of the few on the market, it has the highest content of hyaluronic acid in a single dose.
Biolevox™ HA Tendon
Biolevox™ HA Tendon is a hyaluronic acid administered around the tendon or into the tendon sheath. Biolevox™ HA Tendon is a gel with an optimal concentration of 1.6%, volume of 2 ml and molecular mass. Biolevox™ HA Tendon can reduce the level of perceived pain and leads to a substantial recovery of the functionality of the tendon affected by the tendinopathy process- process that is a consequence of prolonged tendon overload or trauma, mostly related to sports activity. The action of Biolevox™ HA Tendon is based on a strong anti-catabolic function. Administration of the product to the place where, due tendinopathy, the metabolic balance is disturbed, allows to restore tissue homeostasis.
Chondrectoms were designed to allow an easy separation of damaged and calcified cartilage layer from subchondral surface, leaving at the same time the intact subchondral plate. Chondrectoms unique shape as well as special setup of theirs cutting edge allow precise shaping of the cartilage lesions, and formation of perpendicular walls of the defect. Tools can be used in every anatomical situation (every direction of approach) and in either open or arthroscopically approach.
MONOSHOT HA 2.5% + PRP MONOSHOT HA 2.5%, MONOSHOT PRP tube, accessories kit
MONOSHOT is a procedure pack intended for intra-articular injection of hyaluronic acid (HA) enriched with platelet-rich plasma (PRP). MONOSHOT provides the simultaneous lubricating and shock-absorbing effect of hyaluronic acid with optimally selected physicochemical parameters as well as the regenerative effect of growth factors secreted by platelets contained in PRP, obtained with the use of MONOSHOT tube. Intra-articular injection of MONOSHOT HA 2.5% with PRP brings the stronger effect, because of the combined effect of the ingredients.
Ossylbone™ three-dimensional structures Biomimetic bone filler
Bone defects are common and are associated with a significant burden of disease. Importantly, effective clinical management of bone defects remains challenging. Ossylbone™ 3D structures are biomimetic bone fillers in a form of a solid, porous blocks, cylinders or wedges, in many different sizes. Product is delivered in ready-to-use solid form, packed individually. Ossylbone™ 3D structures have been designed in order to create optimal conditions for new bone formation, as product creates immediate scaffold with high initial mechanical strength, interconnected pores and controlled resorption. Product is available in two composition variants, consisting of: • 100% β-TCP – product with markedly reduced resorption rate that supports rapid bone remodeling • 75% HAp and 25% β-TCP – product with tailored resorption rate that provides optimal balance between bone growth and material degradation Material is fully biocompatible, biodegradable, safe and it supports the regeneration of bone tissue.
Wint™ Kit
Wint ™ kit allows to obtain an autologous preparation from the patient’s peripheral blood, containing increased amount of the DKK-1 protein, which is a natural inhibitor of the Wnt signaling pathway. Excessive activation of the Wnt signaling pathway in the joint tissues plays important role in the development of osteoarthritis. The use of an intra-articular Wnt signaling pathway inhibitor is a highly innovative therapy that stays in line with the newest state-of-the-art approaches and strategies in the treatment of osteoarthritis.
Xerthra™ BMAC Bone marrow concentration kit
The Xerthra™ BMAC is a procedure pack dedicated for an easy and efficient concentration of bone marrow. Xerthra™ BMAC provides a final product that contains high concentration of both mesenchymal stem cells- fundamental cellular elements of all regenerative processes, as well as platelets- key anabolic initiators of these processes. As a result, Xerthra™ BMAC can be used in many orthopedic procedures, including but not limited to: • regeneration of the knee meniscus after reconstruction, • intra-articular treatment of patients with osteoarthritis, • biological reconstruction of cartilage, • bone marrow lesions therapy.
Xerthra™ iPRF kit Xerthra™ separation device, accessories necessary for the procedure
Xerthra™ iPRF kit – procedure pack for isolation of injectable platelet-rich fibrin (iPRF) from the patient’s peripheral blood. In the site of the injection autologous iPRF forms a fibrin network where leukocytes and platelets release cytokines and growth factors over a longer period of time. Xerthra™ iPRF kit guarantees isolation from 15 ml of blood of large amount of iPRF. Adjustable amounts of iPRF allows for the individual approach to the patient needs and the use of the required volume. The obtained preparation remains in the liquid form up to 20 minutes (in 37°C) after preparation, which significantly prolongs the time of application to the target site and guarantees effective penetration into hard-to-reach places. Procedure does not require chemical modification of the blood by addition of the anticoagulant. iPRF thanks to its unique ability for fibrin network creation is recommended to use in the injuries in which the prolongated regulatory as well as regenerative action of cytokines and growth factors is required.
Xerthra™ PRP kit Xerthra™ separation device, accessories necessary for the procedure
Xerthra™ PRP kit – procedure pack for isolation and separation of platelet rich plasma (PRP) from patient’s peripheral blood. Autologous PRP is a fraction of plasma with increased number of leukocytes which synthesize cytokines and higher amounts of platelets which release several types of growth factors for support tissue regeneration and healing processes. Xerthra™ PRP kit guarantees uncomplicated, quick, and precise separation of highly concentrated (up to 12,6x) PRP with leukocytes from small amount of peripheral blood (15 ml with anticoagulant). Xerthra™ PRP kit is recommended for use in the inflammatory phase of the disease when regenerative action of growth factors as well as regulatory action of leukocytes are required.
Xerthra™ PRP PURE kit Xerthra™ separation device, accessories necessary for the procedure
Xerthra™ PRP PURE kit – procedure pack for isolation of platelet-rich plasma with reduced content of leukocytes (LP-PRP) from the patient’s peripheral blood. Autologous LP-PRP contains lower number of leukocytes and increased concentration of platelets rich in several growth factors which support healing of the injury over a shorter period of time with less side effects. Xerthra™ PRP PURE kit guarantees uncomplicated, precise and convenient isolation of concentrated LP-PRP (1 ml) with reduced number of erythrocytes and leukocytes obtained via double centrifugation of freshly drawn peripheral blood (15 ml with anticoagulant). LP-PRP is recommended for use in chronic, degenerative phase of the disease in which not inflammatory action of leukocytes but the regenerative action of growth factors contained in platelets is essential.

Nested Applications

EFORT Webshop


Your one-stop booking platform for all your exhibition, satellite, sponsorship, meeting room, educational and promotional needs, both for during the EFORT congress and also all year long! Check it out now and choose the format and investment that best matches your needs!


Nested Applications

PAST Exhibitors

EFORT Annual Congress | Past Exhibitors

EFORT understands that in order to assess the relevance of your company exhibiting during our EFORT Congresses – it is often useful to see which companies have exhibited at previous EFORT congresses. For your convenience, therefore, please find the complete exhibitor listings for the following annual congresses via the links below:

For any inquiries relating to exhibition, satellites and sponsorship – please contact by using the official exhibitors and sponsorship contact us online form.

Note*: The global Covid-19 pandemic forced EFORT to take the difficult decision to postpone the 21st and 22nd EFORT Annual Congresses that was formerly planned to be held in Vienna, Austria in June 2020 and June-July 2021 respectively.

// ]]>